Botox® (serotype A) is currently available and used to treat various ophthalmological conditions. The aim of our study was to review the current indications, side-effects and updates on the clinical use of botulinum toxin- A (Btx-A) in the field of ophthalmology.
Methods:
A literature search using the keywords “Botulinum Toxin”, “Botulinum Toxin A”, “Botox” and “Ophthalmology” was performed using Pubmed. Articles describing the use of botulinum toxin A were selected and reviewed.
Results:
The uses of Btx-A in ophthalmology can be broadly classified into four categories: eyelid, strabismus, cosmetic and others. In the eyelid, it can be used to treat blepharospasm, hemifacial spasm, apraxia of lid opening or induce ptosis in lid retraction and exposure keratopathy. In strabismus management, it can be injected into overacting muscles to realign the eyes. For cosmesis, it can be used to relax facial muscles to reduce wrinkles while other indications include treatment of chronic dry eye, lacrimal hypersecretion and pain relief in acute angle closure attack. Complications of the injection include local effects like ecchymosis, pain or infection and spillover effects like ptosis, diplopia, lagophthalmos, mid facial weakness and dry eyes.
Conclusion:
The clinical application of botulinum toxin A in ophthalmology is extensive. When considering its application in clinical practice, one should be mindful of the indications, risks and benefits of the procedure. When properly delivered, its potential as an efficacious, minimally-invasive treatment modality can be maximised in patient management.
BreidenbachMABrungerAT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature2004;432(7019):925–9.
2.
ScottAB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology1980;87(10):1044–9.
3.
DuttonJJFowlerAM. Botulinum toxin in ophthalmology. Surv Ophthalmol2007;52(1):13–31.
4.
DennistonAReuserT. The use of botulinum toxin in ophthalmology. Hosp Med2001;62(8):477–9.
5.
CarruthersJFagienSMatarassoSL. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg2004;114(6 Suppl):1S–22S.
6.
SetthawatcharawanichSSathirapanyaPLimapichatKPhabphalK. Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin. Qual Life Res2011;20(9):1519–23.
7.
CostaJEspirito-SantoCBorgesAFerreiraJJCoelhoMMooreP. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev2005;(1):CD004900.
8.
FruehBRNelsonCCKapustiakJFMuschDC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol1988;106(1):45–7.
9.
JankovicJOrmanJ. Botulinum A toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study. Neurology1987;37(4):616–23.
10.
ParkYCLimJKLeeDKYiSD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci1993;8(5):334–40.
11.
GirlandaPQuartaroneASinicropiSNicolosiCMessinaC. Unilateral injection of botulinum toxin in blepharospasm: Single fiber electromyography and blink reflex study. Mov Disord1996;11(1):27–31.
12.
DuttonJJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short- and long-term, local and systemic effects. Surv Ophthalmol1996;41(1):51–65.
13.
TruongDComellaCFernandezHHOndoWG. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord2008;14(5):407–14.
14.
NussgensZRoggenkamperP. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol1997;235(4):197–9.
15.
SampaioCFerreiraJJSimoesFRosasMJMagalhaesMCorreiaAP. DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord1997;12(6):1013–8.
16.
QuagliatoEMCarelliEFVianaMA. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol2010;33(1):27–31.
17.
RiederCRSchestatskyPSocalMPMonteTLFrickeDCostaJ. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol2007;30(1):39–42.
18.
RoggenkamperPJostWHBihariKComesGGrafeS. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm2006;113(3):303–12.
19.
JankovicJ. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol2009;16Suppl 2:14–8.
20.
WabbelsBReichelGFulford-SmithAWrightNRoggenkamperP. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm2011;118(2):233–9.
21.
YoonJSKimJCLeeSY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol2009;23(3):137–41.
22.
DuttonJJWhiteJJRichardMJ. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg2006;22(3):173–7.
23.
ZaguiRMMatayoshiSMouraFC. Adverse effects associated with facial application of botulinum toxin: A systematic review with meta-analysis. Arq Bras Oftalmol2008;71(6):894–901.
24.
DuttonJJBuckleyEG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology1988;95(11):1529–34.
25.
CarruthersJStubbsHA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci1987;14(1):42–5.
26.
BoyleMHMcGwinGJr.FlanaganCEVicinanzoMGLongJA. High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference?Ophthal Plast Reconstr Surg2009;25(2):81–4.
27.
MaurielloJAJr. Blepharospasm, Meige syndrome, and hemifacial spasm: Treatment with botulinum toxin. Neurology1985;35(10):1499–500.
28.
ShorrNSeiffSRKopelmanJ. The use of botulinum toxin in blepharospasm. Am J Ophthalmol1985;99(5):542–6.
29.
OliveiraFCOliveiraGCCarielloAJFelbergSOsakiMH. Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia. Arq Bras Oftalmol2010;73(5):405–8.
30.
CostaPGCardosoIPSaraivaFPRaizaACTanakaLKMatayoshiS. Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment. Arq Bras Oftalmol2006;69(3):319–22.
31.
Horwath-WinterJBergloeffJFloegelIHaller-SchoberEMSchmutO. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol2003;87(1):54–6.
32.
BiglanAW. Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthalmic Surg1994; 25(3): 186–8.
33.
ChuenkongkaewW. Botulinum toxin treatment for upper lid retraction of dysthyroidism. J Med Assoc Thai2003;86(11):1051–4.
34.
DintelmannTSoldJGrehnF. Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease. Ophthalmologe2005;102(3):247–50.
35.
MorgensternKEEvanchanJFosterJACahillKVBurnsJAHolckDE. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthal Plast Reconstr Surg2004;20(3):181–5.
36.
OzkanSBCanDSoylevMFArsanAKDumanS. Chemodenervation in treatment of upper eyelid retraction. Ophthalmologica1997;211(6):387–90.
37.
ShihMJLiaoSLLuHY. A single transcutaneous injection with Botox for dysthyroid lid retraction. Eye (Lond)2004;18(5):466–9.
38.
UddinJMDaviesPD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology2002;109(6):1183–7.
39.
SalourHBagheriBAletahaMBabsharifBKleshadiMAbrishamiM. Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease. Orbit2010;29(2):114–8.
40.
CostaPGSaraivaFPPereiraICMonteiroMLMatayoshiS. Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye (Lond)2009;23(4):767–73.
41.
TraiskFTallstedtL. Thyroid associated ophthalmopathy: Botulinum toxin A in the treatment of upper eyelid retraction–a pilot study. Acta Ophthalmol Scand2001;79(6):585–8.
42.
EllisMFDaniellM. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Experiment Ophthalmol2001;29(6):394–9.
43.
MackieIA. Successful management of three consecutive cases of recurrent corneal erosion with botulinum toxin injections. Eye (Lond)2004;18(7):734–7.
44.
NaikMNGangopadhyayNFernandesMMurthyRHonavarSG. Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox) to induce temporary ptosis for corneal protection. Eye (Lond)2008;22(9):1132–6.
45.
ZadikoffCLangAE. Apraxia in movement disorders. Brain2005;128(Pt 7):1480–97.
46.
ForgetRTozlovanuVIancuABoghenD. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology2002;58(12):1843–6.
47.
KertyEEidalK. Apraxia of eyelid opening: Clinical features and therapy. Eur J Ophthalmol2006;16(2):204–8.
48.
BoghenDTozlovanuVIancuAForgetR. Botulinum toxin therapy for apraxia of lid opening. Ann N Y Acad Sci2002;956:482–3.
49.
DefazioGLivreaPLambertiPDe SalviaRLaddomadaGGiorelliM. Isolated so-called apraxia of eyelid opening: Report of 10 cases and a review of the literature. Eur Neurol1998;39(4):204–10.
50.
KrackPMarionMH. “Apraxia of lid opening,” a focal eyelid dystonia: Clinical study of 32 patients. Mov Disord1994;9(6):610–5.
51.
PiccioneFManciniEToninPBizzariniM. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: Report of two cases. Arch Phys Med Rehabil1997;78(5):525–9.
52.
ClarkeJRSpaltonDJ. Treatment of senile entropion with botulinum toxin. Br J Ophthalmol1988;72(5):361–2.
53.
NeetensARubbensMCSmetH. Botulinum A-toxin treatment of spasmodic entropion of the lower eyelid. Bull Soc Belge Ophtalmol1987;224:105–9.
54.
SteelDHHohHBHarradRACollinsCR. Botulinum toxin for the temporary treatment of involutional lower lid entropion: A clinical and morphological study. Eye (Lond)1997;11(Pt 4):472–5.
55.
RoweFJNoonanCP. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev2009;(2):CD006499.
56.
CarruthersJDKennedyRABagaricD. Botulinum vs adjustable suture surgery in the treatment of horizontal misalignment in adult patients lacking fusion. Arch Ophthalmol1990;108(10):1432–5.
57.
LeeJHarrisSCohenJCooperKMacEwenCJonesS. Results of a prospective randomized trial of botulinum toxin therapy in acute unilateral sixth nerve palsy. J Pediatr Ophthalmol Strabismus1994;31(5):283–6.
58.
TejedorJRodriguezJM. Retreatment of children after surgery for acquired esotropia: Reoperation versus botulinum injection. Br J Ophthalmol1998;82(2):110–4.
59.
TejedorJRodriguezJM. Early retreatment of infantile esotropia: Comparison of reoperation and botulinum toxin. Br J Ophthalmol1999;83(7):783–7.
60.
McNeerKWTuckerMGGuerryCHSpencerRF. Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A. J Pediatr Ophthalmol Strabismus2003;40(5):288–92.
61.
LennerstrandGNordboOATianSEriksson-DerouetBAliT. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand1998;76(1):27–7.
62.
TengtrisornSTreyapunNTantisarasartT. Botulinum A toxin therapy on esotropia in children. J Med Assoc Thai2002;85(11):1189–97.
63.
RuizMFMorenoMSanchez-GarridoCMRodriguezJM. Botulinum treatment of infantile esotropia with abduction nystagmus. J Pediatr Ophthalmol Strabismus2000;37(4):196–205.
64.
CamposECSchiaviCBellusciC. Critical age of botulinum toxin treatment in essential infantile esotropia. J Pediatr Ophthalmol Strabismus2000;37(6):328–32; quiz 54–5.
TejedorJRodriguezJM. Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin. Invest Ophthalmol Vis Sci2001;42(11):2542–6.
67.
SenerECSanacAS. Efficacy and complications of dose increments of botulinum toxin-A in the treatment of horizontal comitant strabismus. Eye (Lond)2000;14(Pt 6):873–8.
68.
ChiaARoyLSeenyenL. Comitant horizontal strabismus: An Asian perspective. Br J Ophthalmol2007;91(10):1337–40.
69.
LiYWuX. Observation of botulinum toxin A management in childhood with intermittent exotropia. Zhonghua Yan Ke Za Zhi2008;44(11):967–71.
70.
SpencerRFTuckerMGChoiRYMcNeerKW. Botulinum toxin management of childhood intermittent exotropia. Ophthalmology1997;104(11):1762–7.
71.
ChuenkongkaewWDulayajindaDDeetaeR. Botulinum toxin treatment of the sixth nerve palsy: An experience of 5-year duration in Thailand. J Med Assoc Thai2001;84(2):171–6.
72.
QuahBLLingYLCheongPYBalakrishnanV. A review of 5 years' experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre. Singapore Med J1999;40(6):405–9.
73.
De Liano SanchezP GomezDiaz-MarotoI VillarejoDe Liano SanchezR GomezDominguezA BonalesFerranI VallsRodriguezA Alzamora. Treatment of sixth nerve palsy of traumatic or tumor etiology using botulinum toxin. Arch Soc Esp Oftalmol2000;75(7):471–6.
74.
HolmesJMBeckRWKipKEDrostePJLeskeDA. Botulinum toxin treatment versus conservative management in acute traumatic sixth nerve palsy or paresis. J AAPOS2000;4(3):145–9.
75.
HolmesJMDrostePJBeckRW. The natural history of acute traumatic sixth nerve palsy or paresis. J AAPOS1998;2(5):265–8.
SanjariMSFalavarjaniKGKashkouliMBAghaiGHNojomiMRostamiH. Botulinum toxin injection with and without electromyographic assistance for treatment of abducens nerve palsy: A pilot study. J AAPOS2008;12(3):259–62.
78.
KaoLYChaoAN. Subtenon injection of botulinum toxin for treatment of traumatic sixth nerve palsy. J Pediatr Ophthalmol Strabismus2003;40(1):27–30.
79.
LeibaHWirthGMAmstutzCLandauK. Long-term results of vertical rectus muscle transposition and botulinum toxin for sixth nerve palsy. J AAPOS2010;14(6):498–501.
80.
NowakowskaOLobaPBroniarczyk-LobaA. The efficacy of vertical rectus transposition and its modalities in patients with abducens nerve palsy. Eur J Ophthalmol2011;21(3):223–7.
81.
StiglmayerNLesinMJuriJIvanisevicMBoicLRogosicV. Treatment of ocular motility disturbances in Graves' disease with botulinum toxin A. Coll Antropol2005;29Suppl 1:41–6.
82.
WuXLinNAiLKWangJHYanLJ. The application of botulinum toxin A in the treatment of restrictive strabismus in thyroid associated ophthalmopathy. Zhonghua Yan Ke Za Zhi2006;42(12):1063–7.
83.
ScottABMagoonEHMcNeerKWStagerDR. Botulinum treatment of childhood strabismus. Ophthalmology1990;97(11):1434–8.
84.
KhanAO. Two horizontal rectus eye muscle surgery combined with botulinum toxin for the treatment of very large angle esotropia. A pilot study. Binocul Vis Strabismus Q2005;20(1):15–20.
85.
OwensPLStromingerMBRubinPAVeronneau-TroutmanS. Large-angle exotropia corrected by intraoperative botulinum toxin A and monocular recession resection surgery. J AAPOS1998;2(3):144–6.
86.
RoweFNoonanC. Complications of botulinum toxin a and their adverse effects. Strabismus2009;17(4):139–42.
87.
HorganSELeeJPBunceC. The long-term use of botulinum toxin for adult strabismus. J Pediatr Ophthalmol Strabismus1998;35(1):9–16; quiz 44–5.
88.
SaidSMeshkinpourACarruthersACarruthersJ. Botulinum toxin A: Its expanding role in dermatology and esthetics. Am J Clin Dermatol2003;4(9):609–16.
89.
CarruthersJALoweNJMenterMAGibsonJNordquistMMordauntJ. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol2002;46(6):840–9.
90.
RubinMGDoverJGlogauRGGoldbergDJGoldmanMPSchlessingerJ. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol2009;8(5):439–44.
91.
BrandtFSwansonNBaumannLHuberB. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: Efficacy and safety. Dermatol Surg2009;35(12):1893–901.
92.
GrimesPEShabazzD. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg2009;35(3):429–35; discussion 35–6.
93.
HariiKKawashimaM. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg2008;32(5):724–30.
94.
KawashimaMHariiK. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol2009;48(7):768–76.
95.
WuYZhaoGLiHZhengZZhongSYangZ. Botulinum toxin type A for the treatment of glabellar lines in Chinese: A double-blind, randomized, placebo-controlled study. Dermatol Surg2010;36(1):102–8.
96.
RubinMDoverJMaasCNestorM. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J2009;29(6 Suppl):S50–6.
97.
CohenJLSchlessingerJCoxSELinX. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J2009;29(6 Suppl):S43–9.
98.
MonheitGCarruthersABrandtFRandR. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg2007;33(1 Spec No.):S51–9.
99.
LowePLPatnaikRLoweNJ. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol Surg2005;31(12):1651–4.
100.
LoweNJAscherBHeckmannMKumarCFraczekSEadieN. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg2005;31(3):257–62.
101.
ChajchirIModiPChajchirA. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck. Aesthetic Plast Surg2008;32(5):715–22; discussion 23.
102.
FramptonJEEasthopeSE. Botulinum toxin A (Botox Cosmetic): A review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol2003;4(10):709–25.
103.
BarananoDEMillerNR. Long term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome. Br J Ophthalmol2004;88(4):588–9.
104.
BirchJFVarmaSKNarulaAA. Botulinum toxoid in the management of gustatory sweating (Frey's syndrome) after superficial parotidectomy. Br J Plast Surg1999;52(3):230–1.
105.
HofmannRJ. Treatment of Frey's syndrome (gustatory sweating) and ‘crocodile tears’ (gustatory epiphora) with purified botulinum toxin. Ophthal Plast Reconstr Surg2000;16(4):289–91.
106.
KeeganDJGeerlingGLeeJPBlakeGCollinJRPlantGT. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol2002;86(1):43–6.
107.
KyrmizakisDEPangalosAPapadakisCELogothetisJMaroudiasNJHelidonisES. The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg2004;62(7):840–4.
108.
SahlinSLinderothR. Eyelid botulinum toxin injections for the dry eye. Dev Ophthalmol2008;41:187–92.
109.
SahlinSChenEKaugesaarTAlmqvistHKjellbergKLennerstrandG. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol2000;129(4):481–6.
110.
ChienKHLuDWChenYHChengJHChenJT. Relief of periorbital pain after acute angle closure glaucoma attack by botulinum toxin type A. J Glaucoma2010;19(8):546–50.
